AbbVie strikes $10.9 billion deal for Apogee Therapeutics

AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline.

AbbVie has offered $135.11 per Apogee share held, which implies a 49.49% premium to Thursday's close. Shares of Apogee were at $136.3 in premarket trading.

The deal gives AbbVie access to Apogee's lead drug candidate, zumilokibart, an experimental treatment targeting a range of inflammatory diseases, including moderate-to-severe atopic dermatitis and asthma.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 22, 2026 at 6:08 AM.